Keyphrases
Cholera
100%
Peru
100%
Live Attenuated
100%
Oral Cholera Vaccine
100%
Age Groups
66%
Phase II Study
66%
Immunogenic
66%
Immunogenicity
66%
Adult children
66%
Bangladesh
33%
Whole Cell
33%
HIV-positive
33%
Life-limiting Conditions
33%
Measles Virus
33%
Further Development
33%
Protective Efficacy
33%
All Ages
33%
Young Infants
33%
Vaccine Candidate
33%
Endemic Countries
33%
Resource-limited Settings
33%
Children Infants
33%
Bangladeshi
33%
Good Safety
33%
Vibrio Cholerae O1
33%
V. Cholerae O1
33%
El Tor Biotype
33%
Single-dose Vaccine
33%
Immunology and Microbiology
Cholera Vaccine
100%
Immunogenicity
20%
Colony-Forming Unit
20%
Colony Forming Unit S
20%
Low Drug Dose
10%
Human Immunodeficiency Virus
10%
Serotype
10%
Whole Cell
10%
Measles Vaccine
10%
Vibrio Cholerae O1
10%
Biovar
10%
Pharmacology, Toxicology and Pharmaceutical Science
Cholera Vaccine
100%
Cholera
40%
Immunogenicity
20%
Infection
10%
HIV
10%
Measles Vaccine
10%
El Tor
10%
Vibrio Cholerae O1
10%
Diseases
10%